TORONTO (PRWEB) May 20, 2020
Dry powder inhalation (DPI) drug products are rightfully developed with efficacy and safety in mind to serve critical patient needs. However, as early drug development progresses to clinical development, the ability to efficiently manufacture these products becomes a more important determinant of eventual commercial feasibility.
Whether a DPI product can be manufactured at scale is dependent upon a variety of factors from chemical and physical properties of the formulation to manufacturing conditions.
In this webinar, these factors will be examined as sources of potential process risk. A case study will demonstrate the impact drug formulation can have on processing, product behavior, and performance. Strategies for mitigating process risk will be presented to avoid revisiting formulation development and the corresponding delays that can result.
For more information or to register for this event, visit Inhalation: Connecting Formula to Filling.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.